Amerigen announced that the FDA has approved its Abbreviated New Drug Application (ANDA) for Carbidopa 25mg Tablets, the generic version of Valeant’s Lodosyn. Carbidopa is dopa-decarboxylase inhibitor indicated for the treatment of symptoms of Parkinson’s disease in combination with carbidopa-levodopa (Sinemet) or with levodopa alone.

Administration of carbidopa with levodopa makes more levodopa available for transport to the brain. As it crosses the blood-brain barrier, it is presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa relieves symptoms of Parkinson’s disease.

RELATED: Neurologic Disorders Resource Center

Carbidopa 25mg Tablets are now available for shipping.


Continue Reading

For more information call (732) 993-9827 or visit Amerigenpharma.com.